About Allozyne
Allozyne is a company based in Seattle (United States) founded in 2005 by Dee Datta and William Goddard was acquired by MedImmune in September 2014.. Allozyne has raised $40.46 million across 6 funding rounds from investors including ARE, Arch Venture Partners and MedImmune. The company has 6 employees as of December 31, 2017. Allozyne operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.
- Headquarter Seattle, United States
- Employees 6 as on 31 Dec, 2017
- Founders Dee Datta, William Goddard
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Allozyne, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Allozyne
Allozyne has successfully raised a total of $40.46M across 6 strategic funding rounds. The most recent funding activity was a Series B round of $2.45 million completed in August 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Series B — $2.5M
-
First Round
First Round
(06 Dec 2005)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2013 | Amount | Series B - Allozyne | Valuation |
investors |
|
| Apr, 2013 | Amount | Debt – Conventional - Allozyne | Valuation |
investors |
|
| Jun, 2012 | Amount | Series B - Allozyne | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Allozyne
Allozyne has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include ARE, Arch Venture Partners and MedImmune. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on life science companies
|
Founded Year | Domain | Location | |
|
Early-stage VC investments are focused primarily on US companies.
|
Founded Year | Domain | Location | |
|
Venture capital investments are facilitated by Amgen-backed entity.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Allozyne
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Allozyne
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Allozyne Comparisons
Competitors of Allozyne
Allozyne operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| domain | founded_year | HQ Location |
Small molecule drugs for rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for neurological and neuropsychiatric diseases are developed.
|
|
| domain | founded_year | HQ Location |
Gene and protein therapies are developed for treating various diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Allozyne
Frequently Asked Questions about Allozyne
When was Allozyne founded?
Allozyne was founded in 2005.
Where is Allozyne located?
Allozyne is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Is Allozyne a funded company?
Allozyne is a funded company, having raised a total of $40.46M across 6 funding rounds to date. The company's 1st funding round was a Series B of $2M, raised on Dec 06, 2005.
How many employees does Allozyne have?
As of Dec 31, 2017, the latest employee count at Allozyne is 6.
What does Allozyne do?
Allozyne was founded in 2005 in Seattle, United States, within the biotechnology sector. Technologies are developed and commercialized to enhance efficacy, safety, and dosing of protein-based therapeutics, including peptides, antibodies, and vaccines. A PEGylated IFN beta product was created for multiple sclerosis treatment. Platforms enable amino acid analogue incorporation for improved biologics and next-generation antibody-drug conjugates. The company was acquired by MedImmune in 2014.
Who are the top competitors of Allozyne?
Allozyne's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Neurocrine.
Who are Allozyne's investors?
Allozyne has 7 investors. Key investors include ARE, Arch Venture Partners, MedImmune, Turmeric Acquisition Corp, and OVP Venture Partners.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.